Molecularly targeted therapy: When to stop and when to continue?

The Lancet Oncology

Volumn 11, Issue 8, 2010, Pages 709-711

  Hirsch, Fred R ^a   Mok, Tony S ^b   Borges, Virginia ^a   Bunn, Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; LAPATINIB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77955281431     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70128-5     Document Type: Note

References (13)

1. Mok TS, Wu Y-l, Thongprasert S, et al. Initial treatment of pulmonary adenocarcinoma with gefitinib or carboplatin/paclitaxel. N Engl J Med 2009, 361:947-957.
2. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. Proc Am Soc Clin Oncol 2009, 27. Abstr 3509.
3. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009, 6:352-366.
4. Jackman DM, Miller VA, Ciofreddi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15:5267-5273.
5. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinoma to gefitinib and erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:1-11.
6. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
7. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Clin Oncol 2009, 28:357-360.
8. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
9. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumor. N Engl J Med 2002, 347:472-480.
10. Garfield DH Modern treatment of lung cancer: Response to erlotinib after failure of gefitinib in a patient with advanced non-small cell lung carcinoma. J Clin Oncol 2005, 23:7738-7740.
11. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2 positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27:1999-2006.
12. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
13. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.